Biosimilars: Policy, Practice, and Post Marketing Surveillance to Support Treatment and Coverage Decisions - Proceedings from the AMCP Partnership Forum
Webinar Recorded on June 22, 2021
Many factors increase the complexity of the biologics landscape and the adoption of biosimilars in the U.S. To identify actions that can support the further development and use of biosimilars in the U.S. health care system, and to provide consistent and accurate messages about the value of biosimilars, AMCP held a multidisciplinary stakeholder virtual forum from December 15–16, 2020. Forum participants represented diverse sectors of the healthcare industry, including integrated delivery systems, health plans, pharmacy benefit managers (PBMs), employer groups, biopharmaceutical companies, patient advocacy organizations, health policy researchers, and consulting firms; they considered the strength of different messages and identified gaps in messaging as well as real-world evidence needs. This discussion led to recommendations for language alignment, education, and other ways to improve biosimilar adoption.
- Sonia Oskouei, PharmD, BCMAS, DPLA
Vice President, Biosimilars
- Carly Rodriguez, PharmD, FAMCP
Pharmacy Director, Clinical Innovation